Clinical trial · Interventional
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
NCT01451632CI-TRIAL-00023806completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Other Tumors With EGFR Dependence | — | UNRESOLVED | — |
| Squamous Cell Head and Neck Cancer | — | UNRESOLVED | — |
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
| Irinotecan | Drug | Irinotecan | ALIAS |
| MM-121 | Drug | Seribantumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Part 1: MM-121 + cetuximab
- description
- increasing doses of weekly MM-121 + weekly cetuximab
- interventionNames
- Drug: MM-121
- Drug: Cetuximab
- type
- EXPERIMENTAL
- label
- Part 2: MM-121 + cetuximab + irinotecan
- description
- increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
- interventionNames
- Drug: MM-121
- Drug: Irinotecan
- Drug: Cetuximab
Primary outcomes (3)
- measure
- Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * No standard options remaining * Adequate liver and kidney functions * 18 years of age or above Exclusion Criteria: * History of any secondary active cancer in the last 3 years. * Pregnant or breast feeding * History of severe allergic reactions or contraindications to cetuximab or irinotecan
References
Publications (0)
Data not yet available
No reference posted for this study.